Transcatheter Tricuspid Valve Replacement With the Novel System: 1-Year Outcomes From the TRAVEL Study
- PMID: 40208152
- DOI: 10.1016/j.jcin.2024.12.030
Transcatheter Tricuspid Valve Replacement With the Novel System: 1-Year Outcomes From the TRAVEL Study
Abstract
Background: Transcatheter tricuspid valve replacement (TTVR) is emerging as a promising surgical alternative for high-risk patients with tricuspid regurgitation (TR). Nonetheless, the feasibility of more dedicated devices and the need for additional clinical evidence warrant further exploration.
Objectives: The purpose of this study was to report the 1-year outcomes of the TRAVEL (Transcatheter Right Atrial-Ventricular Valve Replacement With LuX-Valve) study with the LuX-Valve system for patients with severe TR.
Methods: A total of 126 patients with symptomatic severe TR were prospectively enrolled in the single-arm, multicenter TRAVEL study from June 2020 to August 2021. All patients underwent TTVR via the transatrial approach using the LuX-Valve system. The primary endpoint was all-cause mortality and hospitalization for heart failure at 1-year follow-up. Clinical and echocardiographic outcomes were reported.
Results: At baseline, all enrolled patients (mean age 65.8 ± 7.5 years, 79.4% women) were at high surgical risk (mean Society of Thoracic Surgeons score 9.2% ± 4.4%), with severe or greater TR and NYHA functional class ≥ III. In 1-year follow-up, all-cause mortality was 10.3%, and 4.0% of patients were hospitalized for heart failure. TR was reduced to mild or less in 95.2% (P < 0.001), with decreases in right atrial systolic volume (-38.3 ± 21.7 mL; P < 0.001) and mid right ventricular end-systolic diameter (-6.4 ± 2.3 mm; P < 0.001). NYHA functional class I or II was achieved in 79.8% (P < 0.001), and 6-minute walking distance increased by 71.3 ± 42.8 m (P < 0.001).
Conclusions: The 1-year outcomes of the TRAVEL study showed a sustained reduction in TR among patients who underwent LuX-Valve TTVR, accompanied by significant right heart reverse remodeling and improved functional status. Favorable procedural success and survival benefits were also demonstrated. (the TRAVEL Trial: Transcatheter Right Atrial-Ventricular Valve Replacement With LuX-Valve; NCT04436653).
Keywords: LuX-Valve; functional status; survival; transcatheter tricuspid valve replacement; tricuspid regurgitation.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures This work was supported by the Development and Transformation of New Technology and Construction of Precision Diagnosis and Treatment System for Transcatheter Interventional Diagnosis and Treatment of Structural Heart Diseases (2022YFC2503400), the National Key R&D Program of China (2020YFC2008100), and Research on Key Techniques of Minimally Invasive Treatment for Valvular Heart Diseases (2023-YBSF-105). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Similar articles
-
Heterotopic Crosscaval Transcatheter Tricuspid Valve Replacement for Patients With Tricuspid Regurgitation: The Trillium Device.JACC Cardiovasc Interv. 2025 Jun 9;18(11):1425-1434. doi: 10.1016/j.jcin.2025.04.036. JACC Cardiovasc Interv. 2025. PMID: 40500012
-
Impact of Pulmonary Hypertension on Outcomes After Transcatheter Tricuspid Valve Edge-to-Edge Repair.JACC Cardiovasc Interv. 2025 Feb 10;18(3):325-336. doi: 10.1016/j.jcin.2024.10.023. Epub 2024 Oct 28. JACC Cardiovasc Interv. 2025. PMID: 39474983
-
Transcatheter Edge-to-Edge Repair in Patients With Primary Tricuspid Regurgitation.JACC Cardiovasc Interv. 2025 May 26;18(10):1289-1299. doi: 10.1016/j.jcin.2025.03.023. JACC Cardiovasc Interv. 2025. PMID: 40436494
-
Isolated Tricuspid Valve Surgery for Functional Tricuspid Regurgitation.Thorac Cardiovasc Surg. 2025 Mar;73(2):111-116. doi: 10.1055/a-2300-6791. Epub 2024 Apr 5. Thorac Cardiovasc Surg. 2025. PMID: 38580322 Review.
-
Atrioventricular Conduction Disturbances in Patients Undergoing Transcatheter Tricuspid Valve Intervention: A Multidisciplinary Consensus.JACC Cardiovasc Interv. 2025 Jul 28;18(14):1721-1736. doi: 10.1016/j.jcin.2025.06.026. JACC Cardiovasc Interv. 2025. PMID: 40738569 Review.
Cited by
-
Short-term prognosis of patients in different stages of severe tricuspid regurgitation after transcatheter tricuspid-valve replacement.Quant Imaging Med Surg. 2025 Aug 1;15(8):7155-7168. doi: 10.21037/qims-2024-2692. Epub 2025 Jul 29. Quant Imaging Med Surg. 2025. PMID: 40785858 Free PMC article.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical